Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

How long-term data helped justify Revlimid, Genovya price increases to ICER where other drugs faltered
BioCentury | May 1, 2018
Company News

HCV drug sales drag down Gilead's 1Q18 earnings

BioCentury | Feb 3, 2017
Clinical News

Stribild regulatory update

BioCentury | Apr 18, 2016
Company News

Gilead sales and marketing update

BioCentury | Dec 7, 2015
Clinical News

Tenofovir alafenamide fumarate regulatory update

BioCentury | Nov 13, 2015
Clinical News

BMJ publishes 'transparency scorecard'

BioCentury | Nov 6, 2015
Company News

FDA approves Gilead's Genvoya for HIV

Items per page:
1 - 10 of 148